Cyclosporine induces cancer progression by a cell-autonomous mechanism.
about
Posttransplantation malignancy in a patient presenting with weight loss and changed bowel habits: a case reportAntamanide, a derivative of Amanita phalloides, is a novel inhibitor of the mitochondrial permeability transition poreThe latent transforming growth factor beta binding protein (LTBP) familyRegulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin APhosphorylation of NFATc4 by p38 mitogen-activated protein kinasesSkin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanismsGrape seed proanthocyanidines and skin cancer prevention: inhibition of oxidative stress and protection of immune systemIs telomerase reactivation associated with the down-regulation of TGF beta receptor-II expression in human breast cancer?Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-betaDownregulation of calcineurin activity in cervical carcinomaIncidence, risk factors and outcomes of de novo malignancies post liver transplantationSolid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression managementNeoplastic disease after liver transplantation: Focus on de novo neoplasmsTargeting the mTOR pathway in hepatocellular carcinoma: current state and future trendsSkin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosisMelanoma Risk and Survival among Organ Transplant Recipients.Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateMitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasionCharacterization of a gene encoding two isoforms of a mitochondrial protein up-regulated by cyclosporin A in activated T cellsDefective T cell development and function in calcineurin A beta -deficient micePartial nephrectomy in a patient with a left ventricular assist device.Cyclosporin A reverses chemoresistance in patients with gynecologic malignanciesLong-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experienceDNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance?Cancer incidence in kidney transplant recipients: a study protocol.A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.Cyclosporine A improves adhesion and invasion of mouse preimplantation embryos via upregulating integrin β3 and matrix metalloproteinase-9Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.De novo papillary carcinoma in a renal allograft: the pros and cons of immunosuppressionImmunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis.Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) CohortImpact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation.Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.Assessment of immunosuppressant drug carcinogenicity: standard and alternative animal models.Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer developmentFuture prospects for anti-cytokine treatment.
P2860
Q21261410-01355A19-28AE-4C8D-BFE4-101410E4A0D8Q21562115-D6649C77-7189-4373-94BA-FC27DE623177Q24532213-49D42138-B15F-44AD-B014-46CFD3668D97Q24534698-B72DDE73-7BF9-4E1D-A2BD-1A08656CBC54Q24537383-28EAE3FC-B2A6-4ACE-9895-2996010D8F9CQ24655517-9E4DF121-148F-4763-A312-B49AECE9601CQ24656612-DFDD1E94-4A59-4A1F-B936-682CD067CB36Q24791742-26E37BF9-ACFE-4566-AB0E-4F6930E331CAQ24793319-01778B41-E547-4A24-8AD5-FDDB79283862Q24795040-528C3C18-516B-4D93-B7A8-833F2F91B269Q26748580-07FCFA47-3456-47DE-95F2-36BEA02FBE14Q26772295-5E08823C-D5A9-43E6-B705-FF3D2BB18132Q26798306-75C1A69B-C151-493A-BAC5-4F4E5891C548Q26830194-3D81FFAB-2AAC-4E6B-9AE8-6C52E37CC5B9Q26851436-5561E3FD-B5F0-4355-94BE-1280961187BAQ27025406-2C8815B4-D88F-4E1E-800B-AA631D3498EBQ27320787-53E7180B-81D9-40AA-8870-03DF12B563A8Q28067598-F9C2E1BE-3DB5-42B5-9CFC-9C7076176E7AQ28362221-66B5F10B-511A-4C10-8DD2-A60C1751D3AFQ28591382-93E01BE8-8D26-447A-8DF3-D3BFAD8AA405Q28592115-528B8EE3-AB57-454E-A060-4DB9BB9CE709Q30426882-5660A331-9028-4D8C-9F7A-4E5F37440CB9Q33333473-DF13016B-7F15-484D-A020-3B1892B6DAC8Q33346685-BE6EBC16-1131-4CCD-BC40-4C8E84FC6FEFQ33371289-72005122-2B61-42A3-A924-4ED5C07E95A7Q33399015-930F29C1-9BDD-4278-9153-938154C5A501Q33495757-39694461-46B4-4283-A83D-5AF68B963608Q33575450-29DFC36B-0BCA-4877-B3C4-B2F309B75320Q33582900-70723C83-3011-4575-98BD-F63766DA6B04Q33614767-9EF88E2E-3B30-43EE-9635-110961D29E06Q33622320-415484B4-9A76-4DC3-A323-3670FE23C834Q33799731-572E0520-99BC-441E-BE39-841B4917A8F5Q33880261-91E55630-EEFE-4170-B41D-769F3256FA1EQ33905617-ECE075F4-14D2-46AC-8AAB-F4F49E5EA452Q33919087-D9C0C66C-CA0C-4802-AE41-5D18F07E60E9Q33943659-DDFAEBC4-7DB4-4FE9-8323-A346B6AD7210Q33986181-DE7D686F-B805-4719-8D81-02FD35057B00Q34009025-5BE72531-74A4-4091-9CC8-62DBCC500119Q34055699-3D5836A3-94E9-4ECB-B08F-37EE91F297D3Q34071336-12540488-C3C9-4800-8C8C-1549C6F9C0FF
P2860
Cyclosporine induces cancer progression by a cell-autonomous mechanism.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Cyclosporine induces cancer progression by a cell-autonomous mechanism.
@en
Cyclosporine induces cancer progression by a cell-autonomous mechanism.
@nl
type
label
Cyclosporine induces cancer progression by a cell-autonomous mechanism.
@en
Cyclosporine induces cancer progression by a cell-autonomous mechanism.
@nl
prefLabel
Cyclosporine induces cancer progression by a cell-autonomous mechanism.
@en
Cyclosporine induces cancer progression by a cell-autonomous mechanism.
@nl
P2093
P356
P1433
P1476
Cyclosporine induces cancer progression by a cell-autonomous mechanism.
@en
P2093
Maluccio M
Morimoto K
Morimoto T
Suthanthiran M
P2888
P304
P356
10.1038/17401
P407
P577
1999-02-01T00:00:00Z
P6179
1013680268